- Personally signed and dated informed consent document.
- Randomized and treated with subcutaneous investigational product in a tanezumab study
and has completed the study or been withdrawn from the study.
- Actual or planned total knee, hip or shoulder replacement surgery during the tanezumab
- Willing and able to comply with scheduled visits and other study procedures.